199 related articles for article (PubMed ID: 8192442)
1. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.
Leleu G; Kitzis MD; Vallois JM; Gutmann L; Decazes JM
Antimicrob Agents Chemother; 1994 Feb; 38(2):195-9. PubMed ID: 8192442
[TBL] [Abstract][Full Text] [Related]
2. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.
Mentec H; Vallois JM; Bure A; Saleh-Mghir A; Jehl F; Carbon C
Antimicrob Agents Chemother; 1992 Sep; 36(9):1883-9. PubMed ID: 1329634
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.
Rice LB; Carias LL; Shlaes DM
Antimicrob Agents Chemother; 1994 Nov; 38(11):2663-4. PubMed ID: 7872765
[TBL] [Abstract][Full Text] [Related]
4. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae.
Thauvin-Eliopoulos C; Tripodi MF; Moellering RC; Eliopoulos GM
Antimicrob Agents Chemother; 1997 May; 41(5):1053-7. PubMed ID: 9145868
[TBL] [Abstract][Full Text] [Related]
5. Conjugative resistance to tazobactam plus piperacillin among extended-spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae.
Akhan S; Coskunkan F; Tansel O; Vahaboglu H
Scand J Infect Dis; 2001; 33(7):512-5. PubMed ID: 11515761
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
Ambrose PG; Bhavnani SM; Jones RN
Antimicrob Agents Chemother; 2003 May; 47(5):1643-6. PubMed ID: 12709334
[TBL] [Abstract][Full Text] [Related]
7. Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.
Fournier JL; Ramisse F; Jacolot AC; Szatanik M; Petitjean OJ; Alonso JM; Scavizzi MR
Antimicrob Agents Chemother; 1996 Feb; 40(2):325-30. PubMed ID: 8834874
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.
Rice LB; Carias LL; Bonomo RA; Shlaes DM
J Infect Dis; 1996 Jan; 173(1):151-8. PubMed ID: 8537652
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms.
Reese AM; Frei CR; Burgess DS
Int J Antimicrob Agents; 2005 Aug; 26(2):114-9. PubMed ID: 16029947
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.
Kern W; Kennedy SL; Sachdeva M; Sande ER; Gunderson D; Täuber MG
Antimicrob Agents Chemother; 1990 May; 34(5):697-701. PubMed ID: 2163241
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K
Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of the in vitro activity of piperacillin/tazobactam.
Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
[TBL] [Abstract][Full Text] [Related]
13. [Transferability of tazobactam/piperacillin (TAZ/PIPC) to cerebrospinal fluid of rabbit with meningitis caused by Staphylococcus aureus].
Haruta T; Nishio T; Kobayashi Y
Jpn J Antibiot; 1998 Jun; 51(6):432-6. PubMed ID: 9755832
[TBL] [Abstract][Full Text] [Related]
14. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G
J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of multi-drug resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolated from clinical specimens at Bugando Medical Centre, Tanzania to Piperacillin-Tazobactam.
Petro D; Mushi MF; Moremi N; Iddi S; Mirambo M; Seni J; Mshana SE
Tanzan J Health Res; 2014 Jan; 16(1):54-7. PubMed ID: 26867273
[TBL] [Abstract][Full Text] [Related]
16. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
Lister PD
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
[TBL] [Abstract][Full Text] [Related]
17. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
18. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
Lister PD; Prevan AM; Sanders CC
Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
Burgess DS; Waldrep T
Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
